STOCK TITAN

Indivior to Report Third Quarter 2026 Financial Results

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
earnings date

Indivior Pharmaceuticals (INDV) will report its third quarter 2026 financial results on Thursday, October 29, 2026. Results will be released at 7:00 a.m. U.S. EDT and will be available on the company’s website at www.indivior.com.

Loading...
Loading translation...
Argus Oct 19 session 17 alerts
+4.38% close to close 0.9x rel. volume Open Argus
Details

News Market Reaction – SUPN

+2.6% Peak in 1 hr 17 min
$2.35B Mkt Cap at Peak Alert

On Oct 19, the day this news came out, SUPN closed 4.38% above the previous close. Argus tracked a peak move of +2.6% during that session. Our momentum scanner recorded 17 alerts for this stock that day.

Data tracked by StockTitan Argus for the Oct 19 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

RICHMOND, Va., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its third quarter 2026 financial results on Thursday, October 29, 2026. The results will be released at 7:00 a.m. U.S. EDT and will be available on the Company’s website at www.indivior.com.

About Indivior

As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine — developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities, we are powering recovery and renewing hope. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/Indivior.

For Further Information:

InvestorsJason ThompsonVP, Investor Relations
+1 804 402 7123
jason.thompson@indivior.com
MediaCassie France-KellyVP, Communications+1 804 594 0836
Indiviormediacontacts@indivior.com



Keep reading